secwatch.observer — SEC 8-K summary
======================================

Issuer:     Satsuma Pharmaceuticals, Inc. (—)
CIK:        0001692830
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001193125-23-102801
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Satsuma Pharmaceuticals to be acquired for $0.91/share plus CVR by Shin Nippon Biomedical
--------------------------------------------------------------------------------

- Satsuma to be acquired by Shin Nippon Biomedical Laboratories for $0.91 per share plus one contingent value right (CVR) per share.
- Tender offer to commence within 15 business days; closing conditioned on tender of majority of outstanding shares.
- Company received Nasdaq deficiency notice for bid price below $1.00 for 30 consecutive days; has until Oct 9, 2023 to cure.
- CEO John Kollins and CFO Tom O'Neil to be terminated effective upon closing of the merger; directors to resign.
- Termination fee of $905,136 payable by Satsuma under certain circumstances if deal fails.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692830/000119312523102801/0001193125-23-102801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692830/000119312523102801/d481556d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-102801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer